Neovascular Age-related Macular DegenerationNCT04642183
Single In-Clinic Encounter With the Notal Vision Home OCT
An observational study of Neovascular Age-related Macular Degeneration and Intermediate Age Related Macular Degeneration (Disorder), run by Notal Vision Inc. at 1 site in United States.
Trial summary
this is a single In-Clinic Encounter With the Notal Vision Home OCT study. The study population will include up to 50 Age-related Macular Degeneration patients diagnosed with wet NV-AMD in at least one eye at the time of enrollment. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Neovascular Age-related Macular Degeneration, Intermediate Age Related Macular Degeneration (Disorder)
- How many people
- 70 participants
- Where
- 1 siteUnited States
- Study dates
- 16 Nov 2020to 30 Sep 2021
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: The study population will include up to fifty (50) AMD patients diagnosed with wet NV-AMD in at least one eye at the time of enrollment. All subjects will be enrolled at one (1) site in the United States. Patients must meet all inclusion / exclusion criteria. All enrolled subjects should have at least one eye with active (wet) CNV (SRF and/or IRF) at the time of enrollment.
Who may be able to join
- Ability to speak, read and understand English.
- Ability to understand and agree to contents of informed consent either in writing or verbally.
- Eighteen (18) years of age or older at the time of Informed Consent.
- AMD patients diagnosed with wet NV-AMD in at least one eye (ie, with SRF, and/or IRF).
- Fellow eye with NV-AMD (with or without fluid) or intermediate AMD.
- Best corrected Visual Acuity of 20/320 or better in eyes participating at the study.
Who cannot join
- Subjects with dilated pupils.
- Any other retinal disease requiring steroidal or anti-VEGF injections.
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Evaluation of Repeated, In-Clinic, Self-Imaging by NV-AMD Patients Using the Notal Vision Home OCT
this is a single In-Clinic Encounter With the Notal Vision Home OCT study. The study population will include up to 50 Age-related Macular Degeneration patients diagnosed with wet NV-AMD in at least one eye at the time of enrollment. All enrolled subjects should have at least one eye with active (wet) CNV (SRF and/or IRF) at the time of enrollment. All subjects will be enrolled at 1 site in the United States. in this study patients will be placed in a room with the Notal Vision Home OCT device and following a completion of a self tutorial will perform 3 unsupervised self-scans on each study eye (with a rest of ~5 minutes between self-scans). at the end of the testing sessions, the subject will be asked to complete subject user questionnaire.
Read the detailed description
Office Visit:
At the enrollment Office Visit, the exams will be conducted in the following order:
- Patient will be informed concerning the study and sign the Informed Consent Form (ICF) prior to conduct of any study procedures
- The following data will be collected for each study subject:
- Subject's DOB (if allowed) or age
- Gender
- Number and type of injections and last injection date
- Refraction correction
- Snellen BCVA on both eyes on the day of the visit.
- Eligible eyes of the subject will be scanned, non-dilated, with a Zeiss Cirrus OCT device 3 times with one (1) acceptable volume scan of each eye being obtained.
Scanning pattern to be used:
- Macular cube, 6X6mm, 128 B-scans per volume scan NOTE: Any planned treatment for NV-AMD should be administered after completion of all study-related scans.
- Eyes of the subject that meet all screening criteria will be enrolled. NOTE: All enrolled subjects should have at least one eye with active CNV (i.e., with SRF and/or IRF) confirmed by commercial OCT scan(s) at the time of enrollment 7. The following data will be collected for the study eye(s):
- Qualifying diagnosis for the study eye from the subject's medical record
- From the subject's medical record, the presence of other ophthalmic conditions including but not limited to:
- Cataract ii. Glaucoma iii. Dry Eye iv. Other macula findings, e.g., epi retinal membrane, macular hole, vitreo-macular traction (VMT) Following confirmation of subject eligibility, subject will be placed in a room with the NVHO device which has been set up by a clinic technician.
- The clinic technician will register the subject using the touchscreen of the NVHO device.
- The subject will perform a self-tutorial, without any help from the clinic's staff. The training flow begins with demonstration clips followed by a practice phase. The training flow will be followed by a self-scan that the system uses as a calibration session. Note: If an eye cannot calibrate during 3 separate attempts or fails to test 3 consecutive times, the subject will discontinue self-imaging in this eye. If there is a fellow eye also enrolled in the study, the fellow eye will continue.
- Following completion of the training and calibration session, the clinic technician sets the device for testing flows. The subject will perform three (3) unsupervised self-scans on each study eye with a rest period of ~5 minutes between self-scans. In case of scan failures, the user will perform up to 3 additional attempts to complete the required 3 self-scans. The number of attempts will not exceed 3 times per study eye.
- At the end of each self-scanning, and during the 5-minute resting period, image results will be automatically uploaded to Notal Health Cloud. NOTE: Support provided by the sponsor will be available to study subjects throughout the study including tutorial, calibration and scanning, if needed.
- Once the subject completes the testing session in its entirety, the subject will be asked to complete a questionnaire about their experience as a user of the NVHO device and proposed naming options for the device.
- Collect AEs, if applicable.
- Exit the subjects from the study.
- Self-scan data will be backed up on the NVHO device. Commercial Cirrus OCT data will be copied to an external drive and sent to a Notal repository. Study visit data and subject questionnaires responses will be entered into a Sponsor-provided CRF and sent to a Notal repository.
What is being measured
The primary outcome is the main question the study is designed to answer.
Percentage of subjects who completed self-scanning following a self-tutorial.
Percentage of subjects who were able to perform a full self-scanning and generate a retinal volume scan.
Measured: 5-10 minutes
Percentage of eyes that performed 4 self-scans with the same fluid status
Percentage of eyes that performed 4 self-scans, where their fluid status (fluid present/absent) is identical based both human reader and the Notal OCT Analyzer (NOA) artificial-intelligence (AI) module.
Measured: About 30 min - upon completion of the study visit
Agreement between the Cirrus OCT and the NVHO device in detecting fluid in the central 3x3mm of the macula.
Measured: About 30 min - upon completion of the study visit
Summary of subject questionnaire results.
For the multi-choice questions - the average score (1-5) for each question. For open questions - collect the user's feedback for future improvements of the device
Measured: 5-10 minutes
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted24 Nov 2020
- Study start16 Nov 2020
- Primary completion24 Aug 2021
- Study completion30 Sep 2021
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Neovascular Age-related Macular DegenerationStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 70 participants (actual)
Sponsor and investigators
- Lead sponsor
- Notal Vision Inc.
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Michael Elman, MD, Principal investigator, Michael Elman, M.D. 9114 Philadelphia Rd #310 Baltimore, Maryland 21237
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04642183
- Sponsor's protocol ID
- C2020.005
- Status last verified
- Jun 2021
- First submitted
- 11 Nov 2020
- Last updated
- 23 Dec 2021
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 23 Dec 2021. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Evaluation of Repeated, In-Clinic, Self-Imaging by NV-AMD Patients Using the Notal Vision Home OCT
- ClinicalTrials.gov ID
- NCT04642183
- Acronym / sponsor ID
- C2020.005
- Conditions
- Neovascular Age-related Macular Degeneration, Intermediate Age Related Macular Degeneration (Disorder)
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 70 participants (actual)
- Lead sponsor
- Notal Vision Inc.Industry (pharma, biotech, devices)
- Study start
- 16 Nov 2020 (actual)
- Primary completion
- 24 Aug 2021 (actual)
- Study completion
- 30 Sep 2021 (actual)
- First posted
- 24 Nov 2020 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
this is a single In-Clinic Encounter With the Notal Vision Home OCT study. The study population will include up to 50 Age-related Macular Degeneration patients diagnosed with wet NV-AMD in at least one eye at the time of enrollment. All enrolled subjects should have at least one eye with active (wet) CNV (SRF and/or IRF) at the time of enrollment. All subjects will be enrolled at 1 site in the United States. in this study patients will be placed in a room with the Notal Vision Home OCT device and following a completion of a self tutorial will perform 3 unsupervised self-scans on each study eye (with a rest of ~5 minutes between self-scans). at the end of the testing sessions, the subject will be asked to complete subject user questionnaire.
Detailed description
Office Visit:
At the enrollment Office Visit, the exams will be conducted in the following order:
- Patient will be informed concerning the study and sign the Informed Consent Form (ICF) prior to conduct of any study procedures
- The following data will be collected for each study subject:
- Subject's DOB (if allowed) or age
- Gender
- Number and type of injections and last injection date
- Refraction correction
- Snellen BCVA on both eyes on the day of the visit.
- Eligible eyes of the subject will be scanned, non-dilated, with a Zeiss Cirrus OCT device 3 times with one (1) acceptable volume scan of each eye being obtained.
Scanning pattern to be used:
- Macular cube, 6X6mm, 128 B-scans per volume scan NOTE: Any planned treatment for NV-AMD should be administered after completion of all study-related scans.
- Eyes of the subject that meet all screening criteria will be enrolled. NOTE: All enrolled subjects should have at least one eye with active CNV (i.e., with SRF and/or IRF) confirmed by commercial OCT scan(s) at the time of enrollment 7. The following data will be collected for the study eye(s):
- Qualifying diagnosis for the study eye from the subject's medical record
- From the subject's medical record, the presence of other ophthalmic conditions including but not limited to:
- Cataract ii. Glaucoma iii. Dry Eye iv. Other macula findings, e.g., epi retinal membrane, macular hole, vitreo-macular traction (VMT) Following confirmation of subject eligibility, subject will be placed in a room with the NVHO device which has been set up by a clinic technician.
- The clinic technician will register the subject using the touchscreen of the NVHO device.
- The subject will perform a self-tutorial, without any help from the clinic's staff. The training flow begins with demonstration clips followed by a practice phase. The training flow will be followed by a self-scan that the system uses as a calibration session. Note: If an eye cannot calibrate during 3 separate attempts or fails to test 3 consecutive times, the subject will discontinue self-imaging in this eye. If there is a fellow eye also enrolled in the study, the fellow eye will continue.
- Following completion of the training and calibration session, the clinic technician sets the device for testing flows. The subject will perform three (3) unsupervised self-scans on each study eye with a rest period of ~5 minutes between self-scans. In case of scan failures, the user will perform up to 3 additional attempts to complete the required 3 self-scans. The number of attempts will not exceed 3 times per study eye.
- At the end of each self-scanning, and during the 5-minute resting period, image results will be automatically uploaded to Notal Health Cloud. NOTE: Support provided by the sponsor will be available to study subjects throughout the study including tutorial, calibration and scanning, if needed.
- Once the subject completes the testing session in its entirety, the subject will be asked to complete a questionnaire about their experience as a user of the NVHO device and proposed naming options for the device.
- Collect AEs, if applicable.
- Exit the subjects from the study.
- Self-scan data will be backed up on the NVHO device. Commercial Cirrus OCT data will be copied to an external drive and sent to a Notal repository. Study visit data and subject questionnaires responses will be entered into a Sponsor-provided CRF and sent to a Notal repository.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- The study population will include up to fifty (50) AMD patients diagnosed with wet NV-AMD in at least one eye at the time of enrollment. All subjects will be enrolled at one (1) site in the United States. Patients must meet all inclusion / exclusion criteria. All enrolled subjects should have at least one eye with active (wet) CNV (SRF and/or IRF) at the time of enrollment.
Key inclusion criteria (6 listed)
- Ability to speak, read and understand English.
- Ability to understand and agree to contents of informed consent either in writing or verbally.
- Eighteen (18) years of age or older at the time of Informed Consent.
- AMD patients diagnosed with wet NV-AMD in at least one eye (ie, with SRF, and/or IRF).
- Fellow eye with NV-AMD (with or without fluid) or intermediate AMD.
Key exclusion criteria (2 listed)
- Subjects with dilated pupils.
- Any other retinal disease requiring steroidal or anti-VEGF injections.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Percentage of subjects who completed self-scanning following a self-tutorial.
Time frame: 5-10 minutes
Percentage of subjects who were able to perform a full self-scanning and generate a retinal volume scan.
Percentage of eyes that performed 4 self-scans with the same fluid status
Time frame: About 30 min - upon completion of the study visit
Percentage of eyes that performed 4 self-scans, where their fluid status (fluid present/absent) is identical based both human reader and the Notal OCT Analyzer (NOA) artificial-intelligence (AI) module.
Agreement between the Cirrus OCT and the NVHO device in detecting fluid in the central 3x3mm of the macula.
Time frame: About 30 min - upon completion of the study visit
Summary of subject questionnaire results.
Time frame: 5-10 minutes
For the multi-choice questions - the average score (1-5) for each question. For open questions - collect the user's feedback for future improvements of the device
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 23 Dec 2021.
- Individual participant dataSharing planned: Undecided
Related trials for Neovascular Age-related Macular Degeneration
RecruitingPhase 3
A Study of 36-Week Refill Exchanges of Port Delivery System (PDS) With Ranibizumab in nAMD
Neovascular Age-related Macular Degeneration
Active, not recruitingObservational study
Real World Evidence in China: Faricimab Use in Diabetic Macular Edema, Retinal Vein Occlusion, and Neovascular Age-Related Macular Degeneration (The Farseeing Study)
Diabetic Macular Edema, Neovascular Age-related Macular Degeneration
Active, not recruitingPhase 1/2
Phase 1/2 Study of VOY-101 in Patients With Advanced Non-Neovascular Age-Related Macular Degeneration
Age-Related Macular Degeneration, Geographic Atrophy
Active, not recruitingPhase 3
A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer and Tabirafusp Tedromer Compared to Aflibercept in Participants With Neovascular (Wet) Age-related Macular Degeneration (wAMD) - DAYBREAK
Wet Age-related Macular Degeneration
Not yet recruitingPhase 2
A Study to Evaluate the Efficacy and Safety of VIS-101 in Participants With Neovascular Age-Related Macular Degeneration
Neovascular Age Related Macular Degeneration(nAMD)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Michael Elman, MD principal investigator
Michael Elman, M.D. 9114 Philadelphia Rd #310 Baltimore, Maryland 21237
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Neovascular Age-related Macular Degeneration and Intermediate Age Related Macular Degeneration (Disorder), run by Notal Vision Inc. at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 23 Dec 2021. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Percentage of subjects who completed self-scanning following a self-tutorial. (time frame: 5-10 minutes). The study lists 4 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 23 Dec 2021.